DIAMOND AF Post-Approval Study (DAF PAS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Mary Sauline
- Phone Number: 800-633-8766
- Email: mary.k.sauline@medtronic.com
Study Contact Backup
- Name: Jennifer Diouf
- Email: jen.r.diouf@medtronic.com
Study Locations
-
-
-
Pau, France, 64046
- Centre Hospitalier de Pau - Hôpital François Mitterrand
-
Saint-Pierre, France, 97448
- Reunion University Hospital - Saint Pierre
-
-
-
-
-
Ancona, Italy, 60030
- Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona
-
Varese, Italy, 21053
- Humanitas Mater Domini
-
-
-
-
Florida
-
Winter Park, Florida, United States, 32792
- Florida Electrophysiology LLC
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- A diagnosis of recurrent symptomatic paroxysmal AF
- Failure or intolerance of at least one Class I or III antiarrhythmic drug (including sotalol)
- Patient is ≥ 18 years of age
- Planned procedure for the treatment of AF using commercially available DiamondTemp™ Ablation System
- Patient is willing and able to provide written informed consent
- Patient is willing and able to comply with study requirements
Exclusion Criteria:
- Prior persistent AF (continuous AF that is sustained >7 days)
- Patient with life expectancy that makes it unlikely 36 months of follow-up will be completed.
- Current or anticipated participation in any other clinical trial of a drug, device or biologic during the duration of this study not pre-approved by Medtronic
- Patients with contraindications to a Holter monitor
- Unwilling or unable to comply fully with study procedures and follow-up
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Freedom from Atrial Fibrillation (AF) /Atrial Flutter (AFL) /Atrial Tachycardia (AT)
Time Frame: 36 month
|
Estimate the 36-month freedom from AF/AFL/AT recurrence following ablation procedure using the DiamondTemp™ Ablation System.
|
36 month
|
|
Freedom from Primary Safety Events
Time Frame: 12 months
|
Estimate primary safety adverse event rate for ablation using the DiamondTemp™ Ablation System through 12 months.
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Khaldoun Tarakji, MD, Medtronic CAS Chief Medical Officer
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- DIAMOND AF PAS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.